ABPWW
Abpro Holdings Inc
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- +50.0%
- EBITDA
- -1.1%
- EBIT
- +17.4%
- EPS
- +58.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -27.5%
- EBITDA
- +42.9%
- EBIT
- +15.5%
- Net income
- +38.2%
- EPS
- +38.4%
- Free cash flow
- -21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025